CD19 and acute lymphoblastic leukemia: The first approval - granted on August 30th, 2017 – was awarded to 4-1BB-based CD19 CAR T cell therapy tisagenlecleucel (CTL019, Kymriah, Novartis, Basel, Switzerland) for the treatment of patients up to 25 years of age with ALL that is refractory or in second or later relapse [10].